GE HealthCare Technologies Beheer

Beheer criteriumcontroles 0/4

De CEO GE HealthCare Technologies is Pete Arduini, benoemd in Dec2022, heeft een ambtstermijn van 1.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 24.51M, bestaande uit 5.1% salaris en 94.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.003% van de aandelen van het bedrijf, ter waarde € 1.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 1.8 jaar.

Belangrijke informatie

Pete Arduini

Algemeen directeur

US$24.5m

Totale compensatie

Percentage CEO-salaris	5.1%
Dienstverband CEO	1.8yrs
Eigendom CEO	0.003%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Pete Arduini's beloning veranderd ten opzichte van GE HealthCare Technologies's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$25m	US$1m	US$1b
Sep 30 2023	n/a	n/a	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	US$10m	US$1m	US$2b

Compensatie versus markt: De totale vergoeding ($USD 24.51M ) Pete } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 5.07M ).

Compensatie versus inkomsten: De beloning van Pete is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.

CEO

Pete Arduini (59 yo)

1.8yrs

Tenure

US$24,510,947

Compensatie

Mr. Peter J. Arduini, also known as Pete, serves as Director of Ge Healthcare since January 2023. He was a Senior Vice President at General Electric Company since January 2022. He has been President and Ch...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Arduini	President	1.8yrs	US$24.51m	0.0028% € 1.0m
James Saccaro	VP & CFO	1.3yrs	US$10.97m	0.0033% € 1.2m
Taha Kass-Hout	Chief Science & Technology Officer	1.8yrs	US$13.87m	0.0035% € 1.3m
Frank Jimenez	VP, General Counsel & Corporate Secretary	1.8yrs	US$7.51m	0.0047% € 1.7m
George Newcomb	Controller & Chief Accounting Officer	1.8yrs	geen gegevens	0.0012% € 415.9k
Jahid Khandaker	Chief Information Officer	no data	geen gegevens	geen gegevens
Carolynne Borders	Chief Investor Relations Officer	no data	geen gegevens	geen gegevens
Rana Strellis	Chief Corporate Marketing & Communications Officer	no data	geen gegevens	geen gegevens
Adam Holton	Chief People Officer	less than a year	geen gegevens	geen gegevens
Thomas Westrick	President & CEO of Patient Care Solutions	4.8yrs	geen gegevens	0.0014% € 487.6k
Kevin O'Neill	President & CEO of Pharmaceutical Diagnostics	no data	geen gegevens	0.0020% € 713.5k
Roland Rott	President & CEO of Imaging	1.8yrs	geen gegevens	0.0053% € 1.9m

1.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van L0T wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Arduini	President	1.8yrs	US$24.51m	0.0028% € 1.0m
H. Culp	Chairman	1.8yrs	US$531.65k	0.089% € 31.8m
Risa Lavizzo-Mourey	Lead Independent Director	1.8yrs	US$456.65k	0.00023% € 82.5k
Anne Madden	Independent Director	1.8yrs	US$401.61k	0% € 0
William Stromberg	Independent Director	1.8yrs	US$421.58k	0% € 0
Rodney Hochman	Independent Director	1.8yrs	US$401.61k	0% € 0
Lloyd Howell	Independent Director	1.8yrs	US$401.65k	0% € 0
Tomislav Mihaljevic	Independent Director	1.8yrs	US$401.65k	0% € 0
Phoebe Yang	Independent Director	1.8yrs	US$401.65k	0% € 0
Catherine Lesjak	Independent Director	1.8yrs	US$426.65k	0% € 0

1.8yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van L0T wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

GE HealthCare Technologies Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Insider recently sold €1.4m worth of stock

GE Healthcare Names Adam Holton as Chief People Officer

GE HealthCare Technologies Inc., Annual General Meeting, May 21, 2024

Recent updates

GE HealthCare Technologies Inc. Announces Hospital Pulse, the Newest Tile for Its Command Center Software Platform

GE HealthCare Introduces Easy-To-Use, Easy-To-Learn, Easy-To-Appoint Versana Premier Multi-Purpose Ultrasound System

Upcoming dividend of US$0.03 per share

GE Healthcare Accelerates Artificial Intelligence Adoption with New Offering to Advance Enterprise Imaging

GE HealthCare Technologies Inc. to Report Q3, 2024 Results on Oct 30, 2024

GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

GE Healthcare Announces FDA Approval of Flyrcado (Flurpiridaz F 18) Injection Pet Radiotracer for Enhanced Diagnosis of Coronary Artery Disease

Second quarter dividend of US$0.03 announced

GE HealthCare Introduces Elevated Venue Point of Care Ultrasound Solutions and New Tablet-Based Venue Sprint

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

GE HealthCare Technologies Inc. Showcases Latest AI-Enhanced Cardiology Solutions to Enable Real-Time Cardiac Imaging and Assessments At the Point of Care At ESC 2024

GE HealthCare Announces the Publication of the MASTER Trial Results in the Peer-Reviewed Journal Anesthesia and Analgesia

Insider recently sold €1.4m worth of stock

Second quarter 2024 earnings released: EPS: US$0.94 (vs US$0.92 in 2Q 2023)

GE Healthcare Technologies Inc. Updates Earnings Guidance for the Year 2024

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q2, 2024 Results on Jul 31, 2024

First quarter dividend of US$0.03 announced

GE HealthCare Technologies Inc. Announces Cash Dividend for Second Quarter of 2024, Payable on August 15, 2024

GE Healthcare Names Adam Holton as Chief People Officer

GE HealthCare Unveils SIGNA MAGNUS, an FDA 510(K) Pending Head-Only Magnetic Resonance (MR) Scanner Designed to Explore Advance Advancements in Neuro Science

GE HealthCare Launches New Era of AI-Enhanced, Personalized Oncology Solutions at ESTRO 2024 Congress

First quarter 2024 earnings released: EPS: US$0.82 (vs US$0.41 in 1Q 2023)

GE HealthCare Technologies Inc. Reaffirms Earnings Guidance for the Full Year 2024

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women's Health Imaging

Upcoming dividend of US$0.03 per share

GE HealthCare Technologies Inc. to Report Q1, 2024 Results on Apr 30, 2024

GE HealthCare Technologies Inc., Annual General Meeting, May 21, 2024

GE Healthcare Introduces Caption AI on Vscan Air SL Wireless Handheld Ultrasound System to Help More Clinicians Capture Diagnostic-Quality Cardiac Images

GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

GE HealthCare Technologies Inc. to Feature Latest Technologies in Interventional Radiology Focused on Precision Care At Sir 2024

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

Now 23% overvalued after recent price rise

GE HealthCare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $1.06925 billion.

GE HealthCare Technologies Inc. has filed a Follow-on Equity Offering.

New minor risk - Profit margin trend

Full year 2023 earnings released

Now 29% overvalued after recent price rise

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Full Year of 2024

GE HealthCare Technologies Inc. Receives 510(K) Clearance from the United States Food and Drug Administration for Novii™+ Wireless Patch Solution

GE HealthCare Technologies Inc. Announces Prucka 3 Digital Amplifier as Next Generation Platform for Electrophysiology Innovation

Now 20% overvalued after recent price rise

GE HealthCare Technologies Inc. to Report Q4, 2023 Results on Feb 06, 2024

GE HealthCare Technologies Inc. (NasdaqGS:GEHC) entered into definitive agreement to acquire MIM Software Inc.

Upcoming dividend of US$0.03 per share at 0.2% yield

GE HealthCare Highlights Commitment to Delivering Better Patient Experiences and Outcomes Through Deep Learning at RSNA 2023

GE HealthCare Expands On-Device Triage Capabilities of Critical Care Suite with FDA Clearance of Algorithm for Pneumothorax Detection, Notification, Triage and Diagnosis

GE HealthCare Technologies Inc. Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection

GE Healthcare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

GE HealthCare Technologies Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released

GE HealthCare Technologies Inc. Announces to Showcase Some of the Latest Innovations Designed to Help Clinicians in the Treatment of Cardiovascular Disease At the 2023 Transcatheter Cardiovascular Therapeutics Conference

GE HealthCare Technologies Inc. to Report Q3, 2023 Results on Oct 31, 2023

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

GE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

GE HealthCare Launches Enhanced Venue Family Ultrasound Systems Featuring AI-Driven Caption Guidance

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd